{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:42:07Z","timestamp":1775576527096,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cpt.2024.06.007","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T09:40:56Z","timestamp":1719913256000},"page":"76-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Characteristics and outcomes of secondary acute lymphoblastic leukemia (sALL) after multiple myeloma (MM): SEER data analysis in a single-center institution"],"prefix":"10.1016","volume":"3","author":[{"given":"Jing","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanying","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2024.06.007_bib1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","article-title":"Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study","volume":"28","author":"Turesson","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cpt.2024.06.007_bib2","first-page":"4507","article-title":"Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma--a SEER based study","volume":"32","author":"Chakraborty","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cpt.2024.06.007_bib3","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cpt.2024.06.007_bib4","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpt.2024.06.007_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.leu.2403587","article-title":"Acute lymphoblastic leukemia after tandem autologous stem cell transplantations for multiple myeloma","volume":"19","author":"Lau","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.cpt.2024.06.007_bib6","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.5301\/tj.5000377","article-title":"Three patients with multiple myeloma developing secondary lymphoblastic leukemia: case reports and review of the literature","volume":"102","author":"Junxun","year":"2016","journal-title":"Tumori"},{"key":"10.1016\/j.cpt.2024.06.007_bib7","doi-asserted-by":"crossref","first-page":"100757","DOI":"10.1016\/j.blre.2020.100757","article-title":"Second primary malignancies in multiple myeloma: a review","volume":"46","author":"Poh","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.cpt.2024.06.007_bib8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41375-018-0213-y","article-title":"Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma","volume":"33","author":"Aldoss","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.cpt.2024.06.007_bib9","first-page":"1358","article-title":"Multiple primary malignant tumors : a survey of the literature and a statistical study","volume":"16","author":"Warren","year":"1932","journal-title":"Am J Cancer"},{"key":"10.1016\/j.cpt.2024.06.007_bib10","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpt.2024.06.007_bib11","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpt.2024.06.007_bib12","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.24514","article-title":"Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden","volume":"125","author":"Kristinsson","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cpt.2024.06.007_bib13","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","article-title":"Germline mutations in predisposition genes in pediatric cancer","volume":"373","author":"Zhang","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpt.2024.06.007_bib14","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1186\/s12885-019-6286-9","article-title":"B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review","volume":"19","author":"Sinit","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cpt.2024.06.007_bib15","article-title":"Acute lymphoblastic leukemia following lenalidomide maintenance for multiple myeloma: two cases with unexpected presentation and good prognostic features","volume":"2018","author":"Khan","year":"2018","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.cpt.2024.06.007_bib16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/jpm13030412","article-title":"Clinical characteristics and prognosis of secondary acute lymphoblastic leukemia in patients with multiple myeloma during long-term thalidomide maintenance","volume":"13","author":"Liu","year":"2023","journal-title":"J\u00a0Personalized Med"},{"key":"10.1016\/j.cpt.2024.06.007_bib17","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-15-2242","article-title":"Lenalidomide, thalidomide, and pomalidomide reactivate the epstein\u2013barr virus lytic cycle through phosphoinositide 3-kinase signaling and ikaros expression","volume":"22","author":"Jones","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpt.2024.06.007_bib18","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpt.2024.06.007_bib19","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cpt.2024.06.007_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-022-00680-y","article-title":"Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma","volume":"12","author":"Parrondo","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cpt.2024.06.007_bib21","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3109\/10428194.2013.786072","article-title":"Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma","volume":"54","author":"Garc\u00eda-Mu\u00f1oz","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cpt.2024.06.007_bib22","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1182\/blood.2020008609","article-title":"B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide","volume":"137","author":"F\u00fcrstenau","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2024.06.007_bib23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3343\/alm.2019.39.5.496","article-title":"Two rare cases of therapy-related acute lymphoblastic leukemia in patients with plasma cell myeloma","volume":"39","author":"Lee","year":"2019","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.cpt.2024.06.007_bib24","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/bmt.2015.8","article-title":"Therapy-related ALL: cytogenetic features and hematopoietic cell transplantation outcome","volume":"50","author":"Aldoss","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cpt.2024.06.007_bib25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/cam4.1266","article-title":"Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes","volume":"7","author":"Swaika","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.cpt.2024.06.007_bib26","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2024.06.007_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hon.2248","article-title":"Lenalidomide and secondary acute lymphoblastic leukemia: a case series","volume":"35","author":"Tan","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.cpt.2024.06.007_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/10428190109057981","article-title":"Therapy related leukemias: susceptibility, prevention and treatment","volume":"41","author":"Leone","year":"2001","journal-title":"Leuk Lymphoma"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294971322400048X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294971322400048X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T09:03:58Z","timestamp":1736067838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S294971322400048X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S294971322400048X"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2024.06.007","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and outcomes of secondary acute lymphoblastic leukemia (sALL) after multiple myeloma (MM): SEER data analysis in a single-center institution","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2024.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}